RARRES2 and metabolic syndrome: Chemerin is considered a biomarker for adiposity since its plasma levels strongly associate with BMI and is linked to obesity and metabolic syndrome, a cluster of metabolic disorders that increase the risk for diabetes and CVD (Bozaoglu et al., 2009; Li et al., 2014).